Acromegaly in Childhood-Onset Gigantism: Management When Surgery Does Not Normalize GH and IGF-1

Clinical Scenario

This protocol addresses a rare presentation: gigantism caused by a sporadic or familial GH-secreting pituitary adenoma that arose during childhood or puberty, before epiphyseal closure. GH hypersecretion at this developmental stage drives excessive linear growth and the phenotypic features of gigantism through markedly elevated GH and IGF-1 levels.

Previous Treatment & Why This Step Is Needed

Surgery — to resect, ablate, or control the pituitary tumor mass — is the established first-line intervention in gigantism. This protocol applies specifically when surgery has not achieved the primary therapeutic objective: normalization of GH and IGF-1 hypersecretion.

When that goal remains unmet after surgery, a further management step is indicated.

Next-Step Approach (Partial Overview)

Adjuvant medical therapy is the approach considered after surgical failure. The specific agents selected depend on the individual patient's response profile; certain options are reserved for those with resistance to a particular drug class.

The full regimen — including agent selection criteria, sequencing, and all clinical decision points — is available in the complete structured protocol below.

Clinical Goals

Normalization of GH and IGF-1 hypersecretion; control of growth velocity.